Department of Ophthalmology, Tel Aviv Medical Center and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Acta Ophthalmol. 2011 May;89(3):203-7. doi: 10.1111/j.1755-3768.2010.02010.x. Epub 2010 Nov 2.
The aim of this review is to summarize the latest developments in the treatment of diabetic retinopathy (DR) with anti-vascular endothelial growth factor (VEGF) drugs. We reviewed recent studies that evaluated the role of the anti-VEGF agents bevacizumab, ranibizumab and pegaptanib in the treatment of DR. There was only one large randomized controlled trial that evaluated the role of ranibizumab in diabetic macular oedema (DME). Other prospective and retrospective studies provided important insight into the role of anti-VEGF drugs in DR, but most of them were not conducted in large scales. The growing evidence indicates that anti-VEGF drugs are beneficial in DR, especially in DME. Further studies are needed to fully evaluate the role of these agents, especially in proliferative DR and in DR candidates for vitrectomy surgery.
本文旨在综述抗血管内皮生长因子（VEGF）药物治疗糖尿病性视网膜病变（DR）的最新进展。我们回顾了近期评估抗 VEGF 药物贝伐单抗、雷珠单抗和帕珠单抗在 DR 治疗中作用的研究。仅有一项大型随机对照试验评估了雷珠单抗在糖尿病黄斑水肿（DME）中的作用。其他前瞻性和回顾性研究为抗 VEGF 药物在 DR 中的作用提供了重要的见解，但大多数研究规模较小。越来越多的证据表明，抗 VEGF 药物在 DR 中有益，特别是在 DME 中。需要进一步的研究来充分评估这些药物的作用，特别是在增生性 DR 和 DR 患者行玻璃体切除术的候选者中。
